Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.

被引：17
|
作者：
Li, Hongli
Deng, Jingyu
Ge, Shaohua
Zang, Fenglin
Zhang, Le
Ren, Peng
Wang, Baogui
Cao, Fuliang
Deng, Ting
Liu, Rui
Ning, Tao
Yang, Yuchong
Bai, Ming
Wang, Xia
Ji, Zhi
Duan, Jingjing
Liu, Yong
Zhou, Dejun
Liang, Han
Ba, Yi
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Gastrointestinal Med Oncol, Key Lab Canc Prevent & Therapy, Natl Clin Res Ctr Canc,Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[2] Tianjin Med Univ Inst & Hop, Dept Gastroenterol Surg Oncol, Tianjin, Peoples R China
[3] Tianjin Med Univ Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Dept Gastroenterol,Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[4] Tianjin Med Univ Inst & Hop, Dept Pathol, Tianjin, Peoples R China
[5] Tianjin Med Univ Inst & Hop, Dept Esophageal Canc, Tianjin, Peoples R China
[6] Tianjin Med Univ Inst & Hop, Dept Endoscopy, Tianjin, Peoples R China
[7] Tianjin Med Univ Canc Inst & Hosp, Dept Gastrointestinal Med Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[8] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[9] Tianjin Med Univ Canc Inst & Hosp, Dept Gastrointestinal Med Oncol, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc,Natl Clin Res Ctr Canc, Tianjin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4050
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Wei, J.
    Lu, X.
    Liu, Q.
    Li, L.
    Liu, S.
    Liu, F.
    Fu, Y.
    Fan, X.
    Yang, J.
    Yang, Y.
    Zhao, Y.
    Guan, W.
    Liu, B.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1316
  • [2] Perioperative epirubicin, oxaliplatin, and capectabine (EOX) in locally advanced resectable gastroesophageal junction and gastric adenocarcinoma.
    Kalachand, Roshni Deepa
    Mongan, Anne-Marie
    Doherty, Mark
    King, Sinead
    O'Farrell, Niamh
    Reynolds, John Vincent
    O'Byrne, Kenneth John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Mehta, Rutika
    Kim, Richard D.
    Shah, Neal
    Carballido, Estrella M.
    Kim, Youngchul
    Imanirad, Iman
    Kim, Dae Won
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li, N.
    Li, Z.
    Fu, Q.
    Zhang, B.
    Zhang, J.
    Wan, X.
    Lu, C.
    Wang, J.
    Deng, W.
    Wei, C.
    Ma, Y.
    Bie, L.
    Wang, M.
    Luo, S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1302 - S1302
  • [5] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li Ning
    Li Zhi
    Fu Qiang
    Zhang Bin
    Zhang Jian
    Wan XiangBin
    Lu Chaomin
    Wang Jinbang
    Deng Wenying
    Wei Chen
    Ma Yijie
    Bie Liangyu
    Wang Mengyu
    Luo Suxia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [6] SHARED: Efficacy and safety of sintilimab in combination with concurrent chemoradiotherapy (cCRT) in patients with locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.
    Wei, Jia
    Lu, Xiaofeng
    Liu, Qin
    Fu, Yao
    Liu, Song
    Yang, Ju
    Wang, Meng
    Zheng, Liming
    Yang, Yang
    Fan, Xiangshan
    Zhao, Yang
    Guan, Wenxian
    Liu, Baorui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] A phase II study of perioperative mFOLFOX chemotherapy plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ), and stomach
    Sun, Weijing
    Saeed, Anwaar
    Al-Rajabi, Raed Moh'd Taiseer
    Kasi, Anup
    Veeramachaneni, Nirmal K.
    Al-Kasspooles, Mazin Mazin
    Baranda, Joaquina Celebre
    Phadnis, Milind
    Godwin, Andrew K.
    Olyaee, Mojtaba
    Madan, Rashna
    Nagji, Alykhan
    Williamson, Stephen K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.
    Sun, Weijing
    Saeed, Anwaar
    Mohd, Raed
    Al-Rajabi, Taiseer
    Kasi, Anup
    Veeramachaneni, Nirmal K.
    Al-Kasspooles, Mazin Francis
    Baranda, Joaquina Celebre
    Phadnis, Milind A.
    Godwin, Andrew K.
    Olyaee, Mojtaba
    Madan, Rashna
    Streeter, Natalie
    Nagji, Alykhan
    Williamson, Stephen K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] MONEO: A phase II study of avelumab plus FLOT in the perioperative treatment for patients with resectable gastric or gastroesophageal junction cancer
    Alsina, M.
    Ponz-Sarvise, M.
    Lopez Garcia, D.
    Gonzalez, M.
    De Andrea, C.
    Gros, A.
    Vivancos, A.
    Jimenez Fonseca, P.
    Diez, M.
    Arrazubi, V.
    Sanz-Garcia, E.
    Martinez de Castro, E.
    Guardeno Sanchez, R.
    Calvo Campos, M.
    Buges Sanchez, C.
    Munoz, F.
    Tabernero, J.
    Villacampa, G.
    Munoz, S.
    Melero, I.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S155 - S156
  • [10] Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma.
    Liu, Ying
    Han, Guangsen
    Li, Hongle
    Zhao, Yuzhou
    Zhuang, Jing
    Wang, Gangcheng
    Li, Baodong
    Wang, Jinbang
    Li, Zhimeng
    Xia, Qingxin
    Ma, Jie
    Zhang, Chengjuan
    Yu, Juan
    Li, Ke
    Xu, Shuning
    Qiao, Lei
    Kuang, Gaizhen
    Li, Danyang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345